High prevalence of hypervariable region 1-specific and -cross-reactive CD4+ T cells in HCV-infected individuals responsive to IFN-α treatment

Virology

Volumn 269, Issue 2, 2000, Pages 313-324

  Del Porto, Paola ^a   Puntoriero, Giulia ^b   Scottà, Cristiano ^a   Nicosia, Alfredo ^b   Piccolella, Enza ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRBM   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

ADULT; AGED; AMINO ACID SEQUENCE; ANTIBODY DETECTION; ANTIGEN ANTIBODY REACTION; ARTICLE; CELL PROLIFERATION; CROSS REACTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS INACTIVATION;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0034630310     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2000.0238     Document Type: Article

References (38)

1. Alter H. To C or not to C: These are the questions. Blood. 85:1995;1681-1695.
2. Bertoletti A., Cham F., McAdam S., Rostron T., Rowland-Jones S., Sabally S., Corrah T., Ariyoshi K., Whittle H. Cytotoxic T cells from human immunodeficiency virus type 2-infected patients frequently cross-react with different human immunodeficiency virus type 1 clades. J. Virol. 72:1998;2439-2448.
3. Botarelli P., Brunetto M. R., Minutello M. A., Calvo P., Unutmaz D., Weiner A. J., Choo Q.-L., Shuster J. R., Kuo G., Bonino F., Houghton M., Abrignani S. T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology. 104:1993;580-587.
4. Casari G., Sander C., Valencia A. A method to predict functional residues in proteins. Nat. Struct. Biol. 2:1995;171-178.
5. Choo Q.-L., Kuo G., Weiner A. I., Overby L. R., Bradley D. W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B hepatitis genome. Science. 244:1989;359-362.
6. Davis G. L., Balart L. A., Schiff E. R., Lindsay K., Bodenheimer H. C., Perrillo R. P., Carey W., Jacobson I. M., Payne J., Dienstag J. L., VanThiel D. H., Tamburro C., Lefkowitch J., Albrecht J., Meschievitz C., Ortego T. J., Gibas A. Treatment of chronic hepatitis C with recombinant interferon alpha: A multicenter, randomized, controlled study. N. Engl. J. Med. 321:1989;1501-1506.
7. Del Porto P., D'Amato M., Fiorillo M. T., Tuosto L., Piccolella E., Sorrentino R. Identification of a novel HLA-B27 subtype by restriction analysis of a cytotoxic γδ T cell clone. J. Immunol. 153:1994;3093-3100.
8. Enomoto N., Sato C. Hepatitis C virus quasispecies populations during chronic hepatitis C infection. Trends Microbiol. 3:1995;445-447.
9. Evavold B. D., Williams S. G., Hsu B. L., Buus S., Allen P. M. Complete dissection of the Hb(64-76) determinant using T helper 1, T helper 2 clones, and T cell hybridomas. J. Immunol. 148:1992;347-353.
10. Evavold B. D., Sloan-Lancaster J., Wilson K. J., Rothbard J. B., Allen P. M. Specific T cell recognition of minimally homologous peptides: Evidence for multiple endogenous ligands. Immunity. 2:1995;655-663.
11. Farci P., Alter H. J., Wong D. C., Miller R. H., Govindarajan S., Egle R., Shapiro M., Purcell R. H. Prevention of hepatitis C virus infection in chimpanzees after antibody mediated in vitro neutralization. Proc. Natl. Acad. Sci. USA. 91:1994;7792-7796.
12. Farci P., Shimoda A., Wong D., Cabezon T., De Gioannis D., Strazzera A., Shimizu Y., Shapiro M., Alter H. J., Purcell R. Prevention of hepatitis C infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc. Natl. Acad. Sci. USA. 93:1996;15394-15399.
13. Ferrari C., Valli A., Galati L., Penna A., Scaccaglia P., Giuberti T., Schianchi C., Missale G., Marin M. G., Fiaccadori F. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infection. Hepatology. 19:1994;286-295.
14. Fox G., Parry N. R., Barnett P. V., McGinn B., Rowlands D. J., Brown F. The cell attachment site of foot and mouth disease virus includes the amino acid sequence RGD (arginine-glycine-aspartic acid). J. Gen. Virol. 70:1989;625-637.
15. + T cells. J. Immunol. 162:1999;696-703.
16. Goudsmit J., Kuiken C. L., Nara P. L. Linear versus conformational variation of V3 neutralization domains of HIV-1 during experimental and natural infection. AIDS. 3:1989;119-123.
17. Hagerty D. T., Allen P. M. Intramolecular mimicry: Identification and analysis of two-cross-reactive T cell epitopes within a single protein. J. Immunol. 155:1995;2993-3001.
18. + T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection. Hepatology. 21:1995;632-638.
19. Javaherian K., Langlois A. J., McDanal C., Ross K. L., Eckler L. I., Jellis C. L., Profy A. T., Rusche J. R., Bolognesi D. P., Putney S. D., Matthews T. J. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc. Natl. Acad. Sci. USA. 86:1989;6768-6772.
20. Kurosaki M., Enomoto N., Marumo F., Sato C. Evolution and selection of hepatitis C virus variants in patients with chronic hepatitis. Virology. 205:1994;161-169.
21. Lasarte J-J., Garcia-Granero M., Lopez A., Casares N., Garcia N., Civeira M-P, Borras-Cuesta F., Prieto J. Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. Hepatology. 288:1998;815-822.
22. Lechmann M., Ihlenfeldt H. G., Braunschweiger I., Giers G., Jung G., Matz B., Kaiser R., Sauerbruch T., Spengler U. T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C-virus positive blood donors without viremia. Hepatology. 24:1996;790-795.
23. Lechner S., Rispeter K., Meisel H., Kraas W., Jung G., Roggendorf M., Zibert A. Antibodies directed to envelope proteins of hepatitis C virus outside of hypervariable region 1. Virology. 243:1998;313-321.
24. Martell M., Esteban J. I., Quer J., Genesca J., Weiner A., Esteban R., Guardia J., Gomez J. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: Quasipecies nature of HCV genome distribution. J. Virol. 66:1992;3225-3229.
25. Mizushima H., Hijikata M., Asabe S., Irota M., Kimura K., Shimotohno K. Two hepatitis C virus glycoprotein E2 products with different C termini. J. Virol. 68:1994;6215-6222.
26. Oldstone M. B. A. Molecular mimicry and autoimmune disease. Cell. 50:1987;819-820.
27. Pessi A., Bianchi E., Bonelli F., Chiappinelli L. Application of the continuous-flow polyamide method to the solid-phase synthesis of a multiple antigen peptide (MAP) based on the sequence of a malaria epitope. J. Chem. Soc. Chem. Commun. 1:1990;8-9.
28. Puntoriero G., Meola A., Lahm A., Zucchelli S., Bruni Ercoli B., Tafi R., Pezzanera M., Mondelli M. U., Cortese R., Tramontano A., Galfré G., Nicosia A. Towards a solution for hepatitis C virus hypervariability: Mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants. EMBO J. 17:1998;3521-3533.
29. Sarobe P., Jauregui J-I, Lasarte J-J, Garcia N., Civeira M-P., Borras-Cuesta F., Prieto J. Production of IL-2 in response to synthetic peptides from hepatitis C virus E1 protein in patients with chronic hepatitis C: Relationship with the response to interferon treatment. J. Hepatol. 25:1996;1-9.
30. Scarselli E., Cerino A., Esposito G., Silini E., Mondelli M., Traboni C. Occurrance of antibodies reactive with more than one variant of the putative envelope glycoprotein (gp70) hypervariable region 1 in viremic hepatitis C virus-infected patients. J. Virol. 69:1995;4407-4412.
31. Shimizu Y. K., Igarashi H., Kiyoara T., Cabezon T., Farci P., Purcell R. H., Yoshikura H. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell culture. Virology. 223:1996;409-412.
32. Shirai M., Arichi T., Chen M., Nishioka M., Ikeda K., Takahashi H., Enomoto N., Saito T., Major M. E., Nakazawa T., Akatsuka T., Feinstone S. M., Berzofsky J. A. T cell recognition of hypervariable region-1 from hepatitis C virus envelope protein with multiple class II MHC molecules in mice and humans: Preferential help for induction of antibodies to the hypervariable region. J. Immunol. 162:1999;568-576.
33. Simmonds P., Holmes E. C., Cha T. A., Chan S.-W., McOmish F., Irvine B., Beall E., Yap P. L., Kolbergand J., Urdea M. S. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J. Gen. Virol. 74:1993;2391-2399.
34. Weiner A. J., Brauer M. J., Rosenblatt J., Richman K. H., Tung J., Crawford K., Bonino F. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope NS1 proteins and the pestivirus envelope glycoproteins. Virology. 180:1991;842-848.
35. Weiner A. J., Geysen H. M., Christopherson C., Hall J. E., Mason T. J., Saracco G., Bonino F., Crawford K., Marion C. D., Crawford K. A., Brunetto M., Barr P. J., Miyamura T., McHutchinson J., Houghton M. Evidence of immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infections. Proc. Natl. Acad. Sci. USA. 89:1992;3468-3472.
36. Zibert A., Schreier E., Roggendorf M. Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. Virology. 208:1995;653-661.
37. Zibert A., Meisel H., Kraas W., Schulz A., Jung G., Roggendorf M. Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus. J. Virol. 25:1997a;1245-1249.
38. Zibert A., Kraas W., Meisel H., Jung G., Roggendorf M. Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus. J. Virol. 71:1997b;4123-4127.